RFS stratified by BCT score in women ≤50 yrs with intermediate RS (16–25). Low BCT score predicted better RFS in all (P=0.007 ...

Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long ...

High-level results from the DESTINY-Breast09 Phase III trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), in ...

Despite past setbacks, Zymeworks' partnerships, potential milestones, and large target markets present significant upside ...

According to the results of the early study, published simultaneously in the New England Journal of Medicine, 92% of patients ...

Puma Biotechnology, Inc. , a biopharmaceutical company, announced that clinical data on neratinib were presented in a poster session at the American Association for Cancer Research (AACR) Annual ...

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced HER2-mutant non-small cell lung cancer – particularly those with specific HER2 ...

Zongertinib shows promise for treating HER2-mutant non–small cell lung cancer (NSCLC), with significant activity against brain metastases and low interstitial lung disease risk, explains John Heymach, ...

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced ...

Zongertinib elicited meaningful results in previously treated patients with HER2-mutated, advanced non–small cell lung cancer ...

Zymeworks' financial stability is evident with $76.3 million in revenue in 2024 and a cash runway extending through late 2027 ...

Boehringer Ingelheim's zongertinib shows promising results in lung cancer trial with 71% response rate and 14-month median ...